G
Galapagos NV D
D
GLPG
28.730
USD
-0.13
(-0.45%)
مغلق
حجم التداول
8,820
الربح لكل سهم
-3
العائد الربحي
-
P/E
-9
حجم السوق
1,893,222,850
الأخبار المقالات
العنوان: Galapagos NV
القطاع: Healthcare
الصناعة: Biotechnology
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, aBCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.